934240-59-2

Usage

Uses

Used in Pharmaceutical Synthesis:
1-(4-bromophenoxymethyl)-2-fluorobenzene is used as a key intermediate in the synthesis of various pharmaceuticals. Its unique structure allows for the development of new drugs with specific therapeutic properties, contributing to advancements in medicinal chemistry.
Used in Agrochemical Development:
1-(4-bromophenoxymethyl)-2-fluorobenzene is also utilized in the agrochemical industry, where it serves as a precursor for the synthesis of pesticides and other agrochemicals. Its role in creating effective and targeted agrochemicals helps improve crop protection and yield.
Used in Research and Development:
1-(4-bromophenoxymethyl)-2-fluorobenzene is employed in research and development for the creation of new materials and chemical processes. Its versatility and reactivity make it a valuable tool for scientists working on innovative projects in the chemical and materials science fields.
Used in Chemical Process Optimization:
In the chemical industry, 1-(4-bromophenoxymethyl)-2-fluorobenzene is used to optimize existing processes and develop new ones. Its unique properties can lead to more efficient and sustainable methods for producing a variety of chemical products.

Upstream product

• 446-48-0 o-fluorobenzyl bromide 
• 106-41-2 4-bromo-phenol 
• 100-39-0 benzyl bromide 

Downstream Products

• 934240-60-5 methyl (S)-2-((tert-butoxycarbonyl)amino)-5-(4-((2-fluorobenzyl)oxy)phenyl)-5-oxopentanoate 
• 934585-16-7 2-methyl 1-(phenylmethyl) (2S,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1,2-pyrrolidinedicarboxylate 
• 934585-17-8 2-methyl 1-(phenylmethyl) (2R,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-(hydroxymethyl)-1,2-pyrrolidinedicarboxylate 
• 934585-19-0 (5R)-2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1-{[(phenylmethyl)oxy]carbonyl}-L-proline 
• 934585-18-9 2-methyl 1-(phenylmethyl) (2R,5R)-2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-1,2-pyrrolidinedicarboxylate 
• 1070868-54-0 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-N,N-dimethyl-2-[(methyloxy)methyl]-L-prolinamide 
• 1070868-51-7 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-N-methyl-2-[(methyloxy)methyl]-L-prolinamide 
• 1070868-58-4 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-(hydroxymethyl)-N,N-dimethyl-L-prolinamide 
• 1070868-61-9 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-(hydroxymethyl)-N-methyl-L-prolinamide 
• 1070868-60-8 (5R)-2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-N-methyl-L-prolinamide 
• 1070868-57-3 (5R)-2-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-N,N-dimethyl-L-prolinamide 
• 1070868-42-6 2-methyl 1-(phenylmethyl) (2R,5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-[(methyloxy)methyl]-1,2-pyrrolidinedicarboxylate 
• 1070868-53-9 phenylmethyl (2R,5R)-2-[(dimethylamino)carbonyl]-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-[(methyloxy)methyl]-1-pyrrolidinecarboxylate 
• 1070868-45-9 (5R)-5-(4-{[(2-fluorophenyl)methyl]oxy}phenyl)-2-[(methyloxy)methyl]-1-{[(phenylmethyl)oxy]carbonyl}-L-proline 

Relevant academic research and scientific papers

Preparation method of sodium ion channel blocker CNV1014802 hydrochloride form

The invention relates to the field of pharmaceutical chemicals, in particular to a novel preparation method of sodium ion channel blocker (GSK1014802) CNV1014802 hydrochloride for inhibiting sodium ion internal flow, which is a high-selectivity asymmetric

Synthesis of Vixotrigine, a Use-Dependent Sodium Channel Blocker. Part 1: Development of Bulk Supply Routes to Enable Proof of Concept

Two syntheses of vixotrigine are reported. Route 1, adapted from the medicinal chemistry route, enabled rapid delivery of drug substance for clinical development. Route 2, which was developed to address many of the limitations of Route 1, was used to manu

PHARMACEUTICAL COMPOSITIONS COMPRISING 2-METHOXY-5- (5-TRIFLUOROMETHYL-TETRAZOL-I-YL-BENZYL) - (2S-PHENYL-PIPERIDIN-3S-YL-)

The present invention relates to pharmaceutical compositions comprising the NK1 receptor antagonist [2-Methoxy-5-(5-trifuoromethyl-tetrazol-1-yl)-benzyl]-(2S-phenyl- piperidin-3S-yl)-amine, or a pharmaceutically acceptable salt or solvate thereof, and a sodium channel blocker, as a combined preparation for simultaneous or sequential administration and to the use of such compositions in the treatment of certain disorders, including epilepsy, mood disorders and pain.

PROLINAMIDE DERIVATIVES AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS

The invention relates to quaternary α-aminocarboxyamide derivatives of formula (I) and their pharmaceutically salts or solvates (I) wherein R1 is H or CH3; and R2 is H or CH3, for treating diseases and condition

QUATERNARY ALPHA-AMINOCARBOXAMIDE DERIVATIVE AS MODULATORS OF VOLTAGE-GATED SODIUM CHANNELS

The invention relates to quaternary E-aminocarboxyamide derivatives of formula (I), wherein R1, R2, R3, R4, R5, R6, X, q and n are as defined in claim 1, for treating diseases and conditions mediated by modulation of voltage-gated sodium channels.

PROLINAMIDE DERIVATIVES AS SODIUM CHANNEL MODULATORS

The invention provides a compound of formula (I), a solvate, a salt or prodrug thereof, useful in the treatment of diseases and conditions mediated by modulation of use-dependent voltage-gated sodium channels.